Dr Reddys Laboratories (RDY) Short term Debt (2018 - 2026)

Dr Reddys Laboratories (RDY) has reported Short term Debt for 9 consecutive years, with $630.0 million the latest figure, recorded in Q1 2026.

• Quarterly Short term Debt rose 41.57% year-over-year to $630.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $630.0 million (up 41.57% YoY) and the FY2026 annual result came in at $630.0 million, up 41.57% from the prior year.
• Short term Debt improved to $630.0 million in Q1 2026 per RDY's latest filing, from $445.0 million in the prior quarter.
• Over the last five years, Short term Debt for RDY reached as high as $630.0 million in Q1 2026 and fell as low as $13.0 million in Q1 2022.
• A 5-year average of $238.8 million and a median of $90.0 million in 2023 frame the typical range for Short term Debt.
• Annual changes were most pronounced in 2024 — Short term Debt slumped 82.22% — and 2025, when it soared 2681.25%.
• Year by year, Short term Debt stood at $13.0 million in 2022, then jumped by 592.31% to $90.0 million in 2023, then sank by 82.22% to $16.0 million in 2024, then surged by 2681.25% to $445.0 million in 2025, then soared by 41.57% to $630.0 million in 2026.
• According to Business Quant data, Short term Debt over the past three periods registered $630.0 million, $445.0 million, and $16.0 million for Q1 2026, Q1 2025, and Q1 2024 respectively.